10 Top Insider Stock Buys And Sells In January
Ever heard of the “January effect?” In case you haven’t, a “January effect” is considered a phenomenon in the stock market where stock prices, most commonly of small-cap stocks, rise in the ...
Neurocrine Biosciences Inc (NBIX)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Citadel Investment Group Ken Griffin | 2,538,109 | $346,451,879 | +44% | 0.05% |
| 2. | Renaissance Technologies Jim Simons | 2,489,397 | $339,802,691 | -4% | 0.5% |
| 3. | AQR Capital Management Cliff Asness | 1,896,891 | $258,925,561 | +3% | 0.33% |
| 4. | OrbiMed Advisors Samuel Isaly | 938,120 | $128,053,380 | +211% | 2.63% |
| 5. | Braidwell LP Alex Karnal | 901,790 | $123,094,335 | -2% | 3.64% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $5.96 | 22,300 | Large Shareholder | 3,527,700 | 2011-10-12 | Filing | |
| $5.96 | 1,000 | Large Shareholder | 757,600 | 2011-10-12 | Filing | |
| $5.96 | 6,200 | Large Shareholder | 1,236,665 | 2011-10-12 | Filing | |
| $5.73 | 3,800 | Large Shareholder | 3,505,400 | 2011-10-11 | Filing | |
| $5.59 | 44,700 | Large Shareholder | 3,501,600 | 2011-10-10 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $116.80 | 755 | Officer | 20,190 | 2025-02-13 | Filing | |
| $116.77 | 796 | Officer | 19,544 | 2025-02-13 | Filing | |
| $116.68 | 3,012 | Director | 524,209 | 2025-02-13 | Filing | |
| $116.69 | 2,832 | Director | 521,618 | 2025-02-13 | Filing | |
| $116.69 | 13,831 | Director | 10,673 | 2025-02-13 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 14,782,722 | $2,017,841,559 | 0.04% | |
| 2. | 10,119,641 | $1,381,330,998 | 0.02% | |
| 3. | 4,891,137 | $667,654,967 | 0.02% | |
| 4. | 3,016,425 | $411,742,013 | 0.23% | |
| 5. | 1,875,062 | $255,522,640 | 0.01% |
News See All
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Q4 2024 Earnings Call Transcript
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Q4 2024 Earnings Call Transcript February 6, 2025Neurocrine Biosciences, Inc. misses on earnings expectations.
12 Best Low Risk High Growth Stocks to Invest In
In the past few days, the reintroduction of tariffs by the US government has been a significant factor influencing market dynamics.
10 High Growth Healthcare Stocks to Invest in Now
During lean economic times, investing in healthcare stocks is generally regarded as defensive.
12 Most Profitable Pharmaceutical Stocks Right Now
Healthcare, which includes numerous businesses that offer patient care, conduct research and development of novel treatments, and design, produce, and distribute diagnostic tools and tests, takes the ...
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Q3 2024 Earnings Call Transcript
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Q3 2024 Earnings Call Transcript October 30, 2024Neurocrine Biosciences, Inc. misses on earnings expectations.
10 Most Promising Biotech Stocks According to Hedge Funds
Biotechnology stocks are known for their high risk, making them some of the most volatile in the market.
10 Best Aggressive Growth Stocks to Buy According to Hedge Funds
If you're putting money in the stock market, it's more likely than not that growth is the thing that's on your mind.
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Q2 2024 Earnings Call Transcript
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Q2 2024 Earnings Call Transcript August 1, 2024Neurocrine Biosciences, Inc. misses on earnings expectations.
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Q1 2024 Earnings Call Transcript
Neurocrine Biosciences, Inc. misses on earnings expectations. Reported EPS is $0.4189 EPS, expectations were $1.04. Neurocrine Biosciences, Inc.
Billionaire Hedge Funds
